TradeStation

Get Cash Back and $0 Commissions
+ The Power of TradeStation

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, GS, IMMU and MAXR

Globe Newswire 19-Feb-2019 11:33 AM

CEDARHURST, N.Y., Feb. 19, 2019 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Danske Bank A/S (OTC:DNKEY)
Investors Affected: Purchasers of American Depositary Receipts between January 9, 2014 and October 23, 2018

A class action has commenced on behalf of certain shareholders in Danske Bank A/S. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Danske Bank's Estonian branch was facilitating money laundering through at least March 2016; (ii) a whistleblower had reported the Estonian money laundering to the Company in 2013; (iii) Denmark's Financial Supervisory Authority (the "DFSA") had been investigating the Estonian money laundering since 2014; (iv) Danske Bank had concealed the results of its own internal investigation from the DFSA, further exposing it to regulatory action and fines; (v) Danske Bank had been overstating its historical profits by including the profits derived from its illicit Estonian operations; and (vi) Danske Bank lacked effective internal and reporting controls.

Shareholders may find more information at https://kseclaw.com/securities/danske-bank-a-s/?wire=3

The Goldman Sachs Group, Inc. (NYSE:GS)
Investors Affected: February 28, 2014 - December 17, 2018

A class action has commenced on behalf of certain shareholders in The Goldman Sachs Group, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Goldman Sachs participated in a fraud and money-laundering scheme in collusion with 1Malaysia Development Bhd., a Malaysian state-owned investment fund; (2) the foregoing conduct, when revealed, would foreseeably subject Goldman Sachs to heightened regulatory investigations and enforcement; and (3) as a result, Goldman Sachs's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/the-goldman-sachs-group-inc/?wire=3

Immunomedics, Inc. (NASDAQ:IMMU)
Investors Affected: February 8, 2018 - January 18, 2019

A class action has commenced on behalf of certain shareholders in Immunomedics, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Immunomedics' Morris Plains, New Jersey drug substance manufacturing facility was not in compliance with FDA requirements; (ii) the Company's Quality Control Unit did not possess the authority to investigate and correct critical FDA violations occurring  at  the Morris Plains, New Jersey facility; (iii) the Company suffered a  February 2018 data integrity breach at the Morris Plains, New Jersey facility which, among other issues, included the backdating records and manipulation of bioburden samples; (iv) the Company's Chemistry, Manufacturing and Control data submitted in connection with its BLA for sacituzumab govitecan was insufficient to support FDA approval; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times

Shareholders may find more information at https://kseclaw.com/securities/immunomedics-inc/?wire=3

Maxar Technologies Inc. (NYSE:MAXR)
Investors Affected: March 29, 2018 - January 7, 2019

A class action has commenced on behalf of certain shareholders in Maxar Technologies Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (i) Maxar improperly inflated the value of its intangible assets, among other accounting improprieties; (ii) Maxar's highly-valued WorldView-4 was equipped with CMGs that were faulty and/or ill-suited for their designed and intended purpose; and (iii) as a result, Maxar's public statements were materially false and misleading at all relevant times.

Shareholders may find more information at https://kseclaw.com/securities/maxar-technologies-inc/?wire=3

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 334
Cedarhurst, NY 11516
Email: dk@kclasslaw.com 
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

Image for Press Release 768023

KUZNICKI (002).png

Image for Press Release 768023